Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography.
A sensitive and rapid high-performance liquid chromatography method has been developed to measure the levels of the HIV-1 non-nucleoside reverse transcriptase inhibitor nevirapine in human plasma. The sample pre-treatment consists of a protein precipitation with perchloric acid. A Hypersil ODS column is used at ambient temperature and a wavelength of 280 nm is used for ultraviolet detection. The mobile phase contains acetonitrile and a 60 mM phosphate buffer pH 4.5 (30:70, v/v). The detection limit of the method is 0.05 mg/l using 150 microl of plasma. The lower and upper limit of quantitation are 0.1 mg/l and 10 mg/l, respectively. The average recovery of nevirapine is 101.8% with a variation of 4.6%. The average inter-assay precision is 2.4%, the average intra-assay precision 2.9% and the average accuracy 97%.
Hollanders
R M
RM
Department of Clinical Pharmacy, 533 KF University Medical Center, Nijmegen, The Netherlands.
van Ewijk-Beneken Kolmer
E W
EW
Burger
D M
DM
Wuis
E W
EW
Koopmans
P P
PP
Hekster
Y A
YA
D000328:Adult; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004355:Drug Stability; D005260:Female; D015658:HIV Infections / Q000378:metabolism; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors; D006801:Humans; D019829:Nevirapine / Q000032:analysis* / Q000097:blood / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D018894:Reverse Transcriptase Inhibitors / Q000032:analysis / Q000097:blood / Q000493:pharmacokinetics
D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; D054303:HIV Reverse Transcriptase